source
- Novartis and BMS pause autoimmune CAR-T trials after patient deaths and safety concernsNovartis, Bristol Myers Squibb and several other biotech firms have recently encountered setbacks while developing therapies for autoimmune diseases. Some programs have been completely discontinued…
- China adds CAR-T therapy to national insurance list, slashing price to $40,000China has added a CAR-T therapy to its National Reimbursement Drug List, cutting the price to $40,000. The reduction brings the treatment within the scope of basic medical insurance, improving aff…